|August 20, 2014|
|10:08 EDT||LCI||Lannett does not expect study to significantly impact Digoxin sales|
Lannett commented on the utilization of Digoxin, following a recently published abstract in the Journal of the American College of Cardiology, which suggested a potential increased risk of mortality in patients with newly diagnosed atrial fibrillation. The abstract was based on data of the TREAT-AF study from the U.S. Department of Veterans Affairs healthcare system, the company said. "Digoxin has long been an important treatment option for cardiovascular disease,” said Arthur Bedrosian, CEO of Lannett. “As with most medications, we believe medical care providers will continue to prescribe Digoxin unless a more effective alternative medication is available. The company said it does not expect prescriptions of Digoxin to be significantly impacted by the findings of the JACC study. Digoxin currently represents less than 10 percent of the company’s net revenues." Bedrosian went on to say that the company has "implemented a comprehensive strategy to expand and diversify its product offering by developing products internally, forming strategic alliances and acquiring products complementary to its business."
News For LCI From The Last 14 Days
|September 3, 2015|
|07:50 EDT||LCI||Lannett acquisition provides 'much needed jolt,' says Oppenheimer|
Subscribe for More Information
|September 2, 2015|
|18:39 EDT||LCI||On The Fly: After Hours Movers |
UP AFTER EARNINGS: SeaChange (SEAC), up 4.5%... Planet Fitness (PLNT), up 7.1%. ALSO HIGHER: Geron (GERN), up 19.7% after publishing two papers in The New England Journal of Medicine... Lannett (LCI), up 16.6% after announcing that it will acquire Kremers Urban. DOWN AFTER EARNINGS: Five Below (FIVE), down 9.3%... Verint Systems (VRNT), down 6.1%... Catalent (CTLT), down 4.9%.
|16:36 EDT||LCI||Lannett up 9.1% after announcing that it will acquire Kremers Urban |
|16:35 EDT||LCI||Lannett to acquire Kremers Urban Pharmaceuticals For $1.23B|
Subscribe for More Information
|16:34 EDT||LCI||Lannett to acquire Kremers Urban Pharmaceuticals For $1.23B|
|August 26, 2015|
|08:44 EDT||LCI||Lannett steady execution offers compelling upside, says Susquehanna|
Susquehanna noted Lannett delivered solid Q2 results and outlook and believes its stock price is undervaluing the upside potential from new products and business development. The firm also sees the potential for multiple expansion if volume trends remain steady. Susquehanna reiterated its Positive rating but lowered its price target to $70 from $75 on Lannett shares.
|August 25, 2015|
|16:08 EDT||LCI||Lannett sees FY16 CapEx $60M-$70M|
Which includes $30M to continue the partial fit-out of company-owned buildings. Sees FY16 gross margin as a percentage of net sales of approximately 71%-73%; R&D expense in the range of $33M-$35M; SG&A expense ranging from $57M-$59M, which includes approximately $5M in acquisition-related expenses; The full year effective tax rate to be in the range of 34%-35%.
|16:06 EDT||LCI||Lannett sees FY16 revenue $425M-$435M, consensus $433.55M|
|16:05 EDT||LCI||Lannett reports Q4 EPS 91c, consensus 86c|
Reports Q4 revenue $99.3M, consensus $97.62M.